CRISPR Therapeutics AG is advancing CTX112, an allogeneic CAR T-cell therapy targeting CD19, into clinical trials for relapsed or refractory B-cell malignancies. The market for CAR T-cell therapies is expanding, particularly in hematological cancers, with significant competition from established players like Novartis and Gilead. The successful development of CTX112 could position CRISPR Therapeutics as a key player in the CAR T landscape, especially given the innovative CRISPR-Cas9 gene-editing technology employed. However, the company must navigate regulatory hurdles and demonstrate superior efficacy and safety profiles to differentiate CTX112 from existing therapies.